3 results
Approved WMORecruiting
To evaluate the efficacy of PTC857 in reducing disease progression in subjects with amyotrophic lateral sclerosis (ALS)
Approved WMORecruiting
To assess the safety and efficacy of the FANTOM ENCORE sirolimus-eluting BRS.
Approved WMORecruiting
Dose escalationPrimary• To determine the RP2D of single-agent petosemtamab in mCRC patients who have progressed on chemotherapy, with or without an anti-VEGF therapy, and with an anti-EGFR therapy (if RASwt)Secondary• To characterize the safety and…